CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 55 filers reported holding CATABASIS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 0.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $796,000 | +54.0% | 377,460 | +110.8% | 0.00% | 0.0% |
| Q1 2021 | $517,000 | -22.7% | 179,060 | +72.1% | 0.00% | 0.0% |
| Q2 2020 | $669,000 | +185.9% | 104,045 | +84.7% | 0.00% | – |
| Q1 2020 | $234,000 | -56.8% | 56,330 | -38.5% | 0.00% | – |
| Q4 2019 | $542,000 | +176.5% | 91,645 | +153.1% | 0.00% | – |
| Q3 2019 | $196,000 | -64.2% | 36,204 | -46.6% | 0.00% | – |
| Q2 2019 | $547,000 | -44.4% | 67,819 | -45.4% | 0.00% | -100.0% |
| Q1 2019 | $983,000 | +530.1% | 124,164 | +247.6% | 0.00% | – |
| Q4 2018 | $156,000 | – | 35,719 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soleus Capital Management, L.P. | 775,000 | $2,240,000 | 0.40% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,294,000 | $3,740,000 | 0.29% |
| ArchPoint Investors | 162,826 | $471,000 | 0.13% |
| Ikarian Capital, LLC | 852,998 | $2,464,000 | 0.08% |
| Samsara BioCapital, LLC | 150,000 | $434,000 | 0.08% |
| Perceptive Advisors | 1,933,551 | $5,588,000 | 0.07% |
| Fairmount Funds Management LLC | 53,166 | $154,000 | 0.06% |
| Alyeska Investment Group, L.P. | 1,124,623 | $3,250,000 | 0.04% |
| Alyeska Investment Group, L.P. | 731,303 | $2,113,000 | 0.03% |
| Corient Capital Partners, LLC | 103,523 | $299,000 | 0.03% |